BSE Live
Dec 26, 16:01Prev. Close
1266.35
Open Price
1260.30
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 26, 15:58Prev. Close
1265.80
Open Price
1265.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1269.30 (1500)
| Balance Sheet of Dr Reddys Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 85.20 | 85.10 | 84.90 | 84.80 | 84.60 | |
| Total Share Capital | 85.20 | 85.10 | 84.90 | 84.80 | 84.60 | |
| Reserves and Surplus | 10,548.80 | 9,243.90 | 7,698.50 | 6,633.00 | 5,935.60 | |
| Total Reserves and Surplus | 10,548.80 | 9,243.90 | 7,698.50 | 6,633.00 | 5,935.60 | |
| Total Shareholders Funds | 10,634.00 | 9,329.00 | 7,783.40 | 6,717.80 | 6,020.20 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 939.10 | 901.50 | 6.30 | 513.00 | 513.00 | |
| Deferred Tax Liabilities [Net] | 129.00 | 125.20 | 93.70 | 20.00 | 100.80 | |
| Other Long Term Liabilities | 25.50 | 4.70 | 2.80 | 6.30 | 6.00 | |
| Long Term Provisions | 49.80 | 33.50 | 29.80 | 21.20 | 19.70 | |
| Total Non-Current Liabilities | 1,143.40 | 1,064.90 | 132.60 | 560.50 | 639.50 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 2,185.70 | 1,763.00 | 1,582.80 | 1,020.40 | 931.10 | |
| Trade Payables | 716.00 | 842.30 | 767.80 | 733.40 | 806.90 | |
| Other Current Liabilities | 1,237.40 | 1,029.40 | 1,301.10 | 984.40 | 588.90 | |
| Short Term Provisions | 539.50 | 479.50 | 421.40 | 324.10 | 276.80 | |
| Total Current Liabilities | 4,678.60 | 4,114.20 | 4,073.10 | 3,062.30 | 2,603.70 | |
| Total Capital And Liabilities | 16,456.00 | 14,508.10 | 11,989.10 | 10,340.60 | 9,263.40 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 3,129.40 | 2,693.70 | 2,335.50 | 1,896.70 | 1,689.30 | |
| Intangible Assets | 120.00 | 54.60 | 51.50 | 0.10 | 1.70 | |
| Capital Work-In-Progress | 488.30 | 576.10 | 423.20 | 617.60 | 546.00 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 3,737.70 | 3,324.40 | 2,810.20 | 2,514.40 | 2,237.00 | |
| Non-Current Investments | 1,760.10 | 1,740.10 | 2,182.60 | 2,270.70 | 2,462.00 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 553.80 | 535.80 | 350.10 | 631.80 | 911.70 | |
| Other Non-Current Assets | 1.10 | 0.00 | 20.90 | 0.00 | 0.00 | |
| Total Non-Current Assets | 6,052.70 | 5,600.30 | 5,363.80 | 5,416.90 | 5,610.70 | |
| CURRENT ASSETS | ||||||
| Current Investments | 2,102.20 | 1,066.40 | 196.60 | 207.00 | 0.00 | |
| Inventories | 1,723.30 | 1,592.10 | 1,526.50 | 1,326.70 | 1,063.20 | |
| Trade Receivables | 4,711.70 | 4,561.50 | 2,963.90 | 1,943.50 | 1,770.50 | |
| Cash And Cash Equivalents | 901.40 | 665.10 | 919.10 | 849.00 | 66.20 | |
| Short Term Loans And Advances | 865.70 | 828.70 | 888.50 | 529.80 | 577.80 | |
| OtherCurrentAssets | 99.00 | 194.00 | 130.70 | 67.70 | 175.00 | |
| Total Current Assets | 10,403.30 | 8,907.80 | 6,625.30 | 4,923.70 | 3,652.70 | |
| Total Assets | 16,456.00 | 14,508.10 | 11,989.10 | 10,340.60 | 9,263.40 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 1,919.40 | 2,051.80 | 2,097.30 | 2,503.90 | 2,488.20 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 1,151.20 | 1,103.10 | 883.70 | 691.40 | 533.70 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 197.30 | 193.10 | 265.00 | 228.50 | 277.30 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 1,252.30 | 1,264.80 | 863.80 | 609.30 | 510.30 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 7,414.60 | 7,405.90 | 6,100.40 | 4,840.50 | 3,671.80 | |
| Other Earnings | 72.40 | 194.80 | 328.60 | 96.20 | 75.90 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 55.87 | 55.87 | 55.87 | 55.87 | 55.87 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 3.20 | 2.30 | 2.50 | 2.50 | 3.30 | |
| Non-Current Investments Unquoted Book Value | 1,886.80 | 1,866.70 | 2,494.70 | 2,616.00 | 2,614.80 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 2,142.20 | 1,076.20 | 201.00 | 208.00 | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
15.12.2025
12.12.2025
25.11.2025
11.11.2025
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz